BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company's core business model revolves around advancing its pipeline of immunotherapy candidates through clinical trials with the ultimate goal of commercialization. Revenue generation is currently absent, as the company is in the development stage, and its financial viability is dependent on securing additional funding ⁴⁰. The primary customer segments, once products are approved, would be patients with advanced metastatic cancers, initially focusing on breast cancer. The company relies heavily on third-party contract manufacturers for raw materials, active pharmaceutical ingredients, and finished product candidates for clinical trials, and intends to contract with third parties for product development and marketing ³⁰.

The company's lead product candidate is Bria-IMT™, a whole-cell immunotherapy for metastatic breast cancer. This therapy is currently undergoing a pivotal Phase 3 study in combination with an immune checkpoint inhibitor (Retifanlimab) ⁴. Bria-IMT™ is designed to secrete GM-CSF, which stimulates dendritic cells to activate T cells to recognize and destroy tumor cells. The regimen also includes low-dose cyclophosphamide to reduce immune suppression and low-dose local interferon-α to further activate the immune system ⁸. In its Phase 2 study, Bria-IMT™ in combination with immune checkpoint inhibitors demonstrated a median overall survival of 13.4 months ¹¹ for all patients, and 16.5 months ¹¹ for patients treated since 2022 with the Phase 3 formulation. For HR+ metastatic breast cancer patients, the median overall survival was 17.3 months ¹², exceeding TRODELVY® (14.4 months ¹²) and single-agent chemotherapy (11.3 months ¹²). For TNBC patients, the median overall survival was 13.9 months ¹², also outperforming TRODELVY® (11.8 months ¹²) and single-agent chemotherapy (6.9 months ¹²). The intracranial overall response rate (iORR) for patients with intracranial metastatic disease was 71% ¹³.

Another significant product in the pipeline is Bria-OTS™, a personalized off-the-shelf immunotherapy, also known as Bria-BRES™, which is currently in an ongoing Phase 1/2 study in metastatic breast cancer ¹⁷. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines, aiming to provide matched treatment to over 99% of patients ¹⁷. An enhanced version, Bria-OTS+™, is in development for prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™), and melanoma (Bria-MEL+™), as well as breast cancer (Bria-BRES+™) ¹⁷. The company also has a majority-owned subsidiary, BriaPro Therapeutics Corp., which is developing high-affinity antibodies directed against B7-H3, an immune checkpoint molecule, to be incorporated into the proprietary Bria-TILsRx™ platform ¹⁹. BriaPro's lead drug discovery candidates also include small molecule Protein Kinase C delta (PKCδ) inhibitors ²⁹. Additionally, BriaCell has an exclusive license from the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment ²⁰.

For the fiscal year ended July 31, 2025, BriaCell reported a net loss of $26,311,867 ⁴¹, significantly higher than the net loss of $4,791,466 ⁴¹ for the year ended July 31, 2024. The accumulated deficit as of July 31, 2025, was $111,755,564 ⁴⁰, compared to $85,443,697 ⁴⁰ as of July 31, 2024. Total research, development, and clinical trial costs for the year ended July 31, 2025, amounted to $21,270,678 ⁴², a decrease from $27,177,807 ⁴² in the prior year. General and administrative expenses were $5,934,125 ⁴³ in 2025, compared to $6,152,269 ⁴³ in 2024. Financial income, net, decreased to $114,511 ⁴⁴ in 2025 from $262,566 ⁴⁴ in 2024. The company had a positive working capital of $15,948,588 ⁴⁵ as of July 31, 2025, compared to a negative working capital of $3,807,303 ⁴⁵ as of July 31, 2024. Cash and cash equivalents increased by $10,493,808 ⁴⁶ from July 31, 2024, to July 31, 2025.

The decrease in research, development, and clinical trial costs was primarily due to lower clinical trial sites and investigational drug costs, which decreased from $20,885,903 ⁴⁷ in 2024 to $14,765,112 ⁴⁷ in 2025, reflecting the conclusion of the Bria-IMT™ Phase 1/2a trial. Conversely, wages and salaries within R&D increased from $4,567,307 ⁴⁷ in 2024 to $5,356,806 ⁴⁷ in 2025. Bria-IMT™ Pivotal Phase 3 Study costs increased from $11,594,463 ⁴⁸ in 2024 to $13,511,235 ⁴⁸ in 2025. Bria-OTS™ Phase 1/2a costs totaled $428,233 ⁴⁹ in 2025, up from $nil ⁴⁹ in 2024, due to the trial's initiation. The significant increase in net loss was primarily due to a smaller gain on the fair value of the warrant liability, which was $758,364 ⁵⁰ in 2025 compared to $28,242,472 ⁵⁰ in 2024.

During the fiscal year ended July 31, 2025, BriaCell completed several financings, raising approximately $50.9 million ⁵¹ in gross proceeds. The company announced that its ongoing pivotal Phase 3 clinical study for Bria-IMT™ has consented over 100 and enrolled over 75 patients ¹⁵, with top-line data anticipated as early as H1-2026 ¹⁵. The Data Safety Monitoring Board (DSMB) has completed its first, second, and third reviews of safety events, recommending continuation of the Phase 3 study with no safety concerns ¹⁵. In September 2024, the company announced positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with the FDA for Bria-PROS+™ for prostate cancer, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies [17, 19]. The first patient treated with Bria-OTS™ monotherapy demonstrated complete resolution of a lung metastasis, sustained at 6 months [17, 18]. BriaPro Therapeutics Corp., a majority-owned subsidiary, announced a new initiative in antibody therapeutics, developing high-affinity antibodies against B7-H3, expected to be incorporated into the Bria-TILsRx™ platform ¹⁹.

BriaCell anticipates reporting top-line data for its pivotal Phase 3 clinical study of Bria-IMT™ as early as H1-2026 ¹⁵. The FDA has agreed that improvement in overall survival in the Bria-IMT™ combination arm compared to the physician's choice of treatment arm will be the primary endpoint of the study ¹⁴. The study is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician's choice arm, with an additional 50 patients expected to be enrolled in the Bria-IMT™ regimen alone, who will be eligible for combination therapy after initial post-treatment evaluation but will not be included in the primary analysis ¹⁴. The first interim analysis will occur at 144 events (mortalities) ¹⁵; if the hazard ratio (HR) is ≤ 0.6 ¹⁵, BriaCell will submit a Biologics Licensing Application (BLA) ¹⁵. If the HR is > 0.6 ¹⁵, the study will continue to completion with an HR target of 0.7 ¹⁵.

A major growth area for BriaCell is the advancement of its Bria-IMT™ targeted immunotherapy, which has Fast Track Designation by the FDA, intended to accelerate the review process for novel treatments addressing unmet medical needs ⁴. Positive completion of the pivotal study could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer ⁴. The company plans to target oncologists and breast cancer treatment centers for marketing, focusing initially on patients with metastatic or recurrent breast cancer who have failed at least two prior treatment regimens ¹⁶. This will involve a physician education campaign and potential partnerships with other pharmaceutical companies with an established presence in the oncology space ¹⁶.

Another significant growth vector is the development of Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer ⁴. Bria-OTS™ is engineered to express 15 unique HLA types through 4 independent cell lines, aiming to provide matched treatment to over 99% of patients ¹⁷. The company has secured numerous US and international patents for Bria-OTS™ ¹⁷. In September 2024, BriaCell announced positive feedback from its Pre-IND meeting with the FDA for Bria-PROS+™ for prostate cancer, with the FDA waiving requirements for animal toxicology and pharmacokinetic studies prior to opening the IND [17, 19]. IND filings for these immunotherapy cell lines are anticipated starting in late 2025 or early 2026 ¹⁷.

Operationally, BriaCell expects operating expenses and staffing levels to increase in the future as it advances its clinical programs, scales its operations, and undertakes activities to support potential commercialization ⁴⁰. The company will need to attract, retain, train, and motivate additional qualified personnel and continue developing and improving its operational, financial, and management information systems ⁴⁰. Managing growth will also require effective management of multiple, interdependent relationships with third-party contract research organizations, contract manufacturers, clinical investigators, regulatory authorities, academic collaborators, and suppliers ⁴⁰.

BriaCell does not own or operate manufacturing facilities and depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidates for clinical trials ¹⁶. Bria-IMT™ is manufactured under cGMP pursuant to agreements with UC Davis and FujiFilm Diosynth Biotechnology ¹⁶. The company also entered into a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin-Madison to manufacture Bria-Pros™ for anticipated use in clinical studies ¹⁶. Additional manufacturing facilities may be enlisted as demand grows ¹⁶. The company's corporate offices in Canada are located at Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1, and its corporate and research offices in the United States are located at 2929 Arch Street 3rd Floor, Philadelphia, PA 19104 ²¹. As of August 2025, the company commenced a month-to-month lease arrangement for office and lab space in Philadelphia, Pennsylvania, for approximately $43,000 per month ⁴⁷.

The company anticipates that additional capital will be required to complete its current research and development programs, including future research, additional pre-clinical and toxicology studies, and manufacturing initiatives to prepare for market approval and product launch ⁴². The company intends to raise additional capital through debt or equity financings ⁴². For several months during calendar year 2025, certain directors and officers deferred payment of their fees/compensation until a financing was completed, after which these fees were paid in full ⁵². Certain officers have also indicated willingness to receive a portion of their compensation in shares ⁵². The company continues to reduce expenditure on certain non-core activities while maintaining focus on its Phase 3 Bria-IMT™ pivotal study ⁵².

BriaCell faces substantial risks, including the inherent uncertainty of clinical trials, where positive early-stage results may not predict future success in larger, more diverse patient populations ³⁰. The company is heavily reliant on third parties for manufacturing, pharmaceutical development, and marketing, and any failure by these contractors could adversely affect product development and commercialization ³⁰. There is substantial doubt about the company's ability to continue as a going concern, given recurring losses, including net losses of $26,311,867 ⁴¹ and $4,791,466 ⁴¹ in fiscal years 2025 and 2024, respectively, and an accumulated deficit of $111,755,564 ⁴⁰ as of July 31, 2025. The company's ability to obtain additional financing on acceptable terms is not assured, which could lead to delays or indefinite postponement of research and development ⁴². Intellectual property protection is critical, but patents provide only limited defense, and the company is susceptible to infringement suits, which are expensive and time-consuming ³¹. Changes in legislation and regulations, particularly regarding drug pricing and reimbursement, could affect future revenue and profitability ³⁴. The company is also exposed to data security breaches and cyber-attacks, which could lead to penalties, negative publicity, and operational disruptions ⁴¹. International operations expose the company to country-specific taxation policies, governmental controls, export license requirements, and trade restrictions ⁴¹. Furthermore, the company may be classified as a passive foreign investment company (PFIC) for the taxable year ending July 31, 2025, and possibly succeeding years, which could result in adverse tax consequences for U.S. shareholders ⁴⁵.

Management's message emphasizes the company's commitment to developing novel immunotherapies to transform cancer care, particularly highlighting the advancement of Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer. They underscore the Fast Track Designation by the FDA for Bria-IMT™, which is intended to accelerate the review process for treatments addressing unmet medical needs, and express that positive completion of this study could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer ⁴. Management also points to benchmark-beating patient survival and clinical benefit observed in metastatic breast cancer patients during the Phase 2 study, with a median overall survival of 13.4 months ¹¹ for all patients and 16.5 months ¹¹ for those treated with the Phase 3 formulation since 2022. The three strategic priorities emphasized for the period ahead appear to be: first, the successful completion and regulatory progression of the Bria-IMT™ pivotal Phase 3 study, with top-line data anticipated as early as H1-2026 ¹⁵; second, the continued development and clinical advancement of personalized off-the-shelf immunotherapies like Bria-OTS™ and Bria-PROS+™, leveraging positive FDA feedback and preclinical data [17, 19]; and third, the strategic diversification into next-generation antibody modalities through its subsidiary BriaPro Therapeutics Corp., including the Bria-TILsRx™ platform and novel multitargeting agents ¹⁹.